NEW YORK (GenomeWeb) – NeoGenomics said after the close of the market on Tuesday that is has priced its previously announced underwritten public offering of 7 million shares of its common stock at a public offering price of $21.25 per share.
Gross proceeds to NeoGenomics from the offering are expected to be $148.8 million.
In addition, NeoGenomics has granted the underwriters a 30-day option to purchase up to an additional 1.1 million shares of common stock at the public offering price, less underwriting discounts and commissions.
The company said that it plans to use proceeds from the offering for general corporate purposes, and it may use some of it to acquire or invest in complementary businesses and technologies.
Morgan Stanley, SVB Leerink, and William Blair are representatives of the underwriters and book-running managers for the offering. Cantor Fitzgerald, Craig-Hallum Capital Group, Needham & Company, Raymond James, and Stephens are co-managers for the offering.
The offering is expected to close on May 24.